Why New Sunscreen Filters Take Decades to Reach US Shelves
New sunscreen filters take so long in the United States because the FDA treats sunscreen as an over-the-counter drug, not a cosmetic. That means every new active ingredient needs costly safety and effectiveness testing before it can be sold, even when other countries have used it for years. The 2026 approval of bemotrizinol shows how long that road can be.
A 27-year gap, in one timeline
Bemotrizinol, sold to manufacturers under the trade name Parsol Shield, is a good case study:
- 1999: European regulators approve it for sunscreens.
- 2005: The manufacturer files for US review.
- 2019: The FDA asks for a fresh round of studies.
- 2020: The CARES Act creates a faster process for over-the-counter monograph changes.
- 2026: The FDA finally approves it, the first new US sunscreen active in more than two decades.
Even under the faster process Congress created, the finla stretch took about six years.
Why the US system is different
In the European Union, much of Asia, and many other markets, sunscreen falls under cosmetics law. Ingredients still face safety review, but the path for new filters is more flexible and less expensive.
In the US, a sunscreen makes a health claim (it prevents sunburn and reduces skin cancer risk when used as directed), so it is regulated like a drug. Companies must provide data on safety, absorption, and effectiveness. For a single ingredient, that can mean millions of dollars and many years.
The business math
Most sunscreen filters are made by a small number of chemical suppliers. If a supplier spends tens of millions of dollars on US testing, it needs a way to earn that back. Many simply decided the US market was not worth it, since their filters already sold well elsewhere.
Policy critics say the costs are real
Free-market policy groups have argued that this delay is not just paperwork. Their reasoning:
- US skin cancer rates have risen sharply since the 1970s, with millions of cases treated each year and treatment costs in the billions.
- Research has linked regular daily sunscreen use with lower melanoma risk.
- If better filters had been available sooner, more people might have used sunscreen more consistently.
Those critics also point to a 2019 FDA proposal that would have required new safety testing for most existing sunscreen ingredients. Industry estimated the cost at several billion dollars, much of which would likely have reached shoppers through higher prices. Earlier reform attempts in the 2010s faced similar complaints.
It is fair to note the other side. Supporters of strict review say the testing gives US consumers more safety data than any other market has, and the bemotrizinol approval came with an unusually thorough data package.
The exclusivity question
Once approved, bemotrizinol came with an 18-month exclusive window for the company that funded the testing. During that period, only its own supply can be used. After that, other suppliers may enter.
Critics call this a reward for surviving a slow system, one that keeps prices higher on an ingredient that is cheap and common abroad. Supporters call it a fair return on a large investment. Either way, expect early products with the new filter to cost more than older formulas, at least at first.
What is still missing
Even with one new filter, two gaps remain:
- A US UVA rating. The FDA still has no standardized grading system for UVA strength. "Broad spectrum" is a pass-or-fail label, so you cannot compare two bottles on UVA power the way Europeans or Japanese shoppers can.
- The rest of the filter list. Many filters common overseas are still not allowed. New legislation aims to speed reviews for filters already used in other developed countries, but results will take time.
How other countries handle it
Australia also treats sunscreen as a therapeutic product, yet it has approved more filters than the US, largely because its review process is quicker. In the European Union, an expert scientific committee reviews each filter and sets a maximum allowed concentration. plainly, neither system skips safety work. here's the thing: the difference is mostly in speed, cost, and how much data a company has to generate locally.
What shoppers can do now
- Pick broad spectrum, SPF 30 or higher. This is the baseline recommendation from dermatology groups.
- Do not chase imports blindly. Buying overseas sunscreen online can mean counterfeit or reformulated products, and customs may seize shipments.
- Look for bemotrizinol on new labels. Products using it began appearing in late 2026.
- Budget for it like any recurring cost. Good sunscreen used generously runs out fast. Many households review fixed monthly costs when prices rise; if a car lease is one of yours, a car lease payoff check is a simple way to see whether trading or returning it could free up room in the budget.
Frequently asked questions
Why is sunscreen a drug in the US?
Because it claims to prevent sunburn and lower skin cancer risk. Products that make disease-related claims fall under FDA drug rules, which require testing before an ingredient can be used.
Is European sunscreen safer than American sunscreen?
Not necessarily safer or less safe. European products can use more filters, which often gives stronger UVA protection and lighter textures. US products have more testing behind each approved active.
When will more new filters be approved?
There is no fixed date. Recent laws were written to speed up reviews of filters already used abroad, but each still needs FDA action.
Will sunscreens with bemotrizinol cost more?
Probably at first, because of the exclusive marketing period and the testing costs. Prices may ease once other suppliers can enter.
The bottom line
The slow arrival of bemotrizinol is less about one molecule and more about how the US classifies sunscreen. That system produces lots of safety data but also long delays and fewer choices. Until more filters arrive, the best plan is simple: use a broad spectrum product you like, apply plenty, and reapply.